Trade Invivyd Inc. - IVVD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Invivyd Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.76 |
| Open* | 1.73 |
| 1-Year Change* | -44.73% |
| Day's Range* | 1.65 - 1.76 |
| 52 wk Range | 0.98-4.89 |
| Average Volume (10 days) | 209.70K |
| Average Volume (3 months) | 8.00M |
| Market Cap | 194.27M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 109.76M |
| Revenue | N/A |
| EPS | -1.61 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | 1.70 | -0.03 | -1.73% | 1.73 | 1.76 | 1.65 |
| Sep 28, 2023 | 1.76 | 0.04 | 2.33% | 1.72 | 1.80 | 1.71 |
| Sep 27, 2023 | 1.76 | 0.14 | 8.64% | 1.62 | 1.83 | 1.62 |
| Sep 26, 2023 | 1.63 | 0.02 | 1.24% | 1.61 | 1.66 | 1.57 |
| Sep 25, 2023 | 1.58 | -0.03 | -1.86% | 1.61 | 1.62 | 1.55 |
| Sep 22, 2023 | 1.61 | 0.01 | 0.63% | 1.60 | 1.62 | 1.55 |
| Sep 21, 2023 | 1.64 | -0.09 | -5.20% | 1.73 | 1.75 | 1.62 |
| Sep 20, 2023 | 1.74 | -0.05 | -2.79% | 1.79 | 1.82 | 1.73 |
| Sep 19, 2023 | 1.82 | 0.01 | 0.55% | 1.81 | 1.86 | 1.76 |
| Sep 18, 2023 | 1.84 | 0.07 | 3.95% | 1.77 | 1.85 | 1.77 |
| Sep 15, 2023 | 1.74 | 0.02 | 1.16% | 1.72 | 1.83 | 1.72 |
| Sep 14, 2023 | 1.73 | -0.05 | -2.81% | 1.78 | 1.80 | 1.72 |
| Sep 13, 2023 | 1.75 | -0.11 | -5.91% | 1.86 | 1.95 | 1.75 |
| Sep 12, 2023 | 1.88 | 0.06 | 3.30% | 1.82 | 1.91 | 1.82 |
| Sep 11, 2023 | 1.81 | 0.09 | 5.23% | 1.72 | 1.90 | 1.68 |
| Sep 8, 2023 | 1.76 | 0.01 | 0.57% | 1.75 | 1.79 | 1.66 |
| Sep 7, 2023 | 1.76 | 0.06 | 3.53% | 1.70 | 1.77 | 1.69 |
| Sep 6, 2023 | 1.73 | 0.01 | 0.58% | 1.72 | 1.77 | 1.70 |
| Sep 5, 2023 | 1.80 | 0.01 | 0.56% | 1.79 | 1.83 | 1.69 |
| Sep 1, 2023 | 1.82 | 0.00 | 0.00% | 1.82 | 1.86 | 1.79 |
Invivyd Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Total revenue | 0 | 0 | 0 |
| Total Operating Expense | 230.658 | 226.908 | 65.327 |
| Selling/General/Admin. Expenses, Total | 47.044 | 36.517 | 3.21 |
| Research & Development | 183.614 | 190.391 | 62.117 |
| Operating Income | -230.658 | -226.908 | -65.327 |
| Interest Income (Expense), Net Non-Operating | 3.9 | 1.7 | 0.008 |
| Net Income Before Taxes | -241.317 | -226.79 | -65.319 |
| Net Income After Taxes | -241.317 | -226.79 | -65.319 |
| Net Income Before Extra. Items | -241.317 | -226.79 | -65.319 |
| Net Income | -241.317 | -226.79 | -65.319 |
| Income Available to Common Excl. Extra. Items | -241.317 | -226.79 | -65.319 |
| Income Available to Common Incl. Extra. Items | -241.317 | -226.79 | -65.319 |
| Diluted Net Income | -241.317 | -226.79 | -65.319 |
| Diluted Weighted Average Shares | 108.268 | 42.6213 | 108.516 |
| Diluted EPS Excluding Extraordinary Items | -2.22888 | -5.32105 | -0.60193 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||
| Diluted Normalized EPS | -2.22888 | -5.32105 | -0.60193 |
| Other, Net | -14.559 | -1.582 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 53.875 | 39.071 | 30.839 | 47.331 | 51.749 |
| Selling/General/Admin. Expenses, Total | 10.107 | 11.045 | 10.52 | 13.2 | 14.62 |
| Research & Development | 43.768 | 28.026 | 20.319 | 34.131 | 37.129 |
| Operating Income | -53.875 | -39.071 | -30.839 | -47.331 | -51.749 |
| Interest Income (Expense), Net Non-Operating | 1.6 | 1.1 | 3.8 | 0.1 | |
| Net Income Before Taxes | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Net Income After Taxes | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Net Income Before Extra. Items | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Net Income | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Income Available to Common Excl. Extra. Items | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Income Available to Common Incl. Extra. Items | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Diluted Net Income | -50.228 | -35.321 | -44.574 | -45.087 | -50.99 |
| Diluted Weighted Average Shares | 109.45 | 108.786 | 108.61 | 108.421 | 108.167 |
| Diluted EPS Excluding Extraordinary Items | -0.45891 | -0.32468 | -0.4104 | -0.41585 | -0.4714 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.45891 | -0.32468 | -0.4104 | -0.41585 | -0.4714 |
| Other, Net | 2.047 | 2.65 | -17.535 | 2.244 | 0.659 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Total Current Assets | 376.917 | 616.711 | 117.382 |
| Cash and Short Term Investments | 371.991 | 591.418 | 114.988 |
| Cash & Equivalents | 92.076 | 542.224 | 114.988 |
| Prepaid Expenses | 4.549 | 25.293 | 2.253 |
| Other Current Assets, Total | 0.141 | ||
| Total Assets | 383.167 | 620.091 | 117.382 |
| Total Current Liabilities | 25.031 | 62.06 | 13.072 |
| Accounts Payable | 1.517 | 5.783 | 8.153 |
| Accrued Expenses | 23.47 | 56.277 | 4.919 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Total Liabilities | 27.197 | 62.072 | 13.083 |
| Total Long Term Debt | 0 | 0 | 0 |
| Other Liabilities, Total | 2.166 | 0.012 | 0.011 |
| Total Equity | 355.97 | 558.019 | 104.299 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 169.548 |
| Common Stock | 0.011 | 0.011 | 0 |
| Additional Paid-In Capital | 889.657 | 850.125 | 0.155 |
| Retained Earnings (Accumulated Deficit) | -533.426 | -292.109 | -65.319 |
| Treasury Stock - Common | -0.085 | ||
| Total Liabilities & Shareholders’ Equity | 383.167 | 620.091 | 117.382 |
| Total Common Shares Outstanding | 109.044 | 110.783 | 108.516 |
| Short Term Investments | 279.915 | 49.194 | |
| Property/Plant/Equipment, Total - Net | 6.059 | 0.083 | |
| Other Long Term Assets, Total | 0.191 | 3.297 | |
| Other Equity, Total | -0.272 | -0.008 | |
| Total Receivables, Net | 0.377 | ||
| Other Current Liabilities, Total | 0.044 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 344.623 | 376.917 | 421.596 | 481.361 | 554.301 |
| Cash and Short Term Investments | 333.428 | 371.991 | 418.669 | 474.885 | 532.22 |
| Cash & Equivalents | 126.473 | 92.076 | 278.152 | 474.885 | 532.22 |
| Prepaid Expenses | 10.662 | 4.549 | 2.142 | 6.476 | 22.081 |
| Other Current Assets, Total | |||||
| Total Assets | 350.564 | 383.167 | 424.747 | 484.612 | 556.273 |
| Total Current Liabilities | 22.057 | 25.031 | 46.126 | 67.883 | 95.534 |
| Accounts Payable | 5.913 | 1.517 | 16.77 | 14.232 | 18.682 |
| Accrued Expenses | 16.086 | 23.47 | 29.303 | 53.593 | 76.852 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 23.815 | 27.197 | 47.304 | 69.773 | 96.881 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 1.758 | 2.166 | 1.178 | 1.89 | 1.347 |
| Total Equity | 326.749 | 355.97 | 377.443 | 414.839 | 459.392 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.011 | 0.011 | 0.011 | 0.011 | 0.011 |
| Additional Paid-In Capital | 895.6 | 889.657 | 866.238 | 858.593 | 852.156 |
| Retained Earnings (Accumulated Deficit) | -568.747 | -533.426 | -488.852 | -443.765 | -392.775 |
| Treasury Stock - Common | 0 | 0 | 0 | ||
| Total Liabilities & Shareholders’ Equity | 350.564 | 383.167 | 424.747 | 484.612 | 556.273 |
| Total Common Shares Outstanding | 109.316 | 109.044 | 108.957 | 108.781 | 109.675 |
| Other Long Term Assets, Total | 0.291 | 0.191 | 0.236 | 0.299 | 0.237 |
| Short Term Investments | 206.955 | 279.915 | 140.517 | 0 | 0 |
| Total Receivables, Net | 0.533 | 0.377 | 0.785 | ||
| Other Equity, Total | -0.115 | -0.272 | 0.046 | 0 | 0 |
| Property/Plant/Equipment, Total - Net | 5.65 | 6.059 | 2.915 | 2.952 | 1.735 |
| Other Current Liabilities, Total | 0.058 | 0.044 | 0.053 | 0.058 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Net income/Starting Line | -241.317 | -226.79 | -65.319 |
| Cash From Operating Activities | -219.987 | -184.736 | -14.571 |
| Non-Cash Items | 37.419 | 19.26 | 40.07 |
| Changes in Working Capital | -16.13 | 22.793 | 10.678 |
| Cash From Financing Activities | 0.506 | 662.683 | 129.559 |
| Issuance (Retirement) of Stock, Net | 0.506 | 666.068 | 129.559 |
| Net Change in Cash | -450.148 | 427.236 | 114.988 |
| Cash From Operating Activities | 0.041 | 0.001 | |
| Cash From Investing Activities | -230.667 | -50.711 | |
| Capital Expenditures | -1.705 | -0.084 | |
| Other Investing Cash Flow Items, Total | -228.962 | -50.627 | |
| Financing Cash Flow Items | 0 | -3.385 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -35.321 | -241.317 | -196.743 | -151.656 | -100.666 |
| Cash From Operating Activities | -41.181 | -219.987 | -172.583 | -116.441 | -59.049 |
| Non-Cash Items | 3.236 | 37.419 | 16.077 | 8.749 | 2.257 |
| Changes in Working Capital | -9.216 | -16.13 | 8.069 | 26.457 | 39.356 |
| Cash From Financing Activities | 0.542 | 0.506 | 0.365 | 0.119 | 0.045 |
| Issuance (Retirement) of Stock, Net | 0.542 | 0.506 | 0.365 | 0.119 | 0.045 |
| Net Change in Cash | 34.397 | -450.148 | -264.072 | -67.339 | -10.004 |
| Financing Cash Flow Items | 0 | 0 | 0 | ||
| Cash From Investing Activities | 75.036 | -230.667 | -91.854 | 48.983 | 49 |
| Other Investing Cash Flow Items, Total | 75.66 | -228.962 | -91.36 | 49 | 49 |
| Cash From Operating Activities | 0.12 | 0.041 | 0.014 | 0.009 | 0.004 |
| Capital Expenditures | -0.624 | -1.705 | -0.494 | -0.017 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Adimab, L.L.C. | Corporation | 24.3158 | 26687906 | 0 | 2022-06-22 | |
| Mithril Capital Management LLC | Venture Capital | 10.2424 | 11241580 | 0 | 2022-07-05 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 9.0559 | 9939351 | -4009584 | 2023-06-30 | LOW |
| M28 Capital Management LP | Investment Advisor | 8.4262 | 9248250 | 0 | 2023-06-30 | MED |
| Polaris Venture Partners | Venture Capital | 7.7734 | 8531700 | 0 | 2022-06-22 | LOW |
| Alphabet, Inc. | Venture Capital | 5.1758 | 5680785 | 0 | 2023-06-30 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 4.8019 | 5270400 | 0 | 2023-06-30 | LOW |
| 683 Capital Management LLC | Hedge Fund | 3.6445 | 4000000 | 600000 | 2023-06-30 | MED |
| Slate Path Capital LP | Investment Advisor | 3.403 | 3735000 | 0 | 2023-06-30 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.2678 | 2489014 | -210968 | 2023-06-30 | LOW |
| Maverick Capital, Ltd. | Hedge Fund | 2.1305 | 2338373 | 450846 | 2023-06-30 | MED |
| Citi Investment Research (US) | Research Firm | 2.1203 | 2327146 | 2325904 | 2023-06-30 | MED |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 1.765 | 1937207 | 0 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.7638 | 1935875 | 409716 | 2023-06-30 | HIGH |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 1.3127 | 1440725 | 0 | 2023-06-30 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.1351 | 1245823 | -2192562 | 2023-06-30 | LOW |
| Population Health Partners, L.P. | Corporation | 1.0949 | 1201680 | 0 | 2022-06-22 | |
| Tang Capital Management, LLC | Hedge Fund | 1.0495 | 1151843 | 751843 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4716 | 517594 | -519603 | 2023-06-30 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2716 | 298100 | -10000 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Invivyd Inc. Company profile
About Adagio Therapeutics Inc
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).
| Industry: | Bio Therapeutic Drugs |
1601 Trapelo Road
Suite 178
WALTHAM
MASSACHUSETTS 02451
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com